• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Alcon Inc. - Articles and news items

transcend-medical

Eye care company Alcon acquires Transcend Medical

Industry news / 18 February 2016 / Victoria White

This Transcend Medical acquisition also expands Alcon’s leadership in glaucoma and cataract treatment…

Novartis

Alcon’s Simbrinza® approved in the EU to treat patients living with glaucoma, a chronic sight-threatening eye disease

Industry news / 28 July 2014 / Novartis

Alcon, the global leader in eye care and a division of Novartis, announced that Simbrinza® eye drops suspension (brinzolamide 10mg/mL and brimonidine tartrate 2mg/mL) has been approved by the European Commission…

Novartis

Novartis emphasizes new focused portfolio at its first Meet Novartis Management investor day

Industry news / 18 June 2014 / Novartis

For its first “Meet Novartis Management” investor day, Novartis gathered more than 20 of its top executives, drawn from the leadership of Pharmaceuticals…

Novartis

Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler retires; Richard Francis named as new Division Head, Sandoz

Industry news / 9 April 2014 / Novartis

Novartis announced the appointment of Jeff George as Division Head of Alcon, effective May 1, 2014…

Alcon Logo

Alcon announces FDA approval of Simbrinza(TM) Suspension

Industry news / 19 April 2013 / Novartis

A new beta blocker-free, fixed-combination therapy for glaucoma patients…

Alcon Logo

Alcon announces EU approval of Jetrea®

Industry news, News / 18 March 2013 / Novartis

Alcon announces EU approval of Jetrea®, first and only eye drug to treat sight-threatening vitreomacular traction and macular hole…

Novartis logo

Jetrea(TM) receives positive CHMP opinion

Industry news, News / 18 January 2013 / Novartis

Jetrea(TM) would become the first drug to treat sight-threatening vitreomacular traction and macular hole…

Novartis logo

Alcon gains exclusive ex-US rights for ocriplasmin

Industry news, News / 16 March 2012 / Novartis

Potential first pharmacological treatment for symptomatic vitreomacular adhesion…

Novartis logo

Novartis shareholders approve merger of Alcon into Novartis

Industry news, News / 8 April 2011 / Novartis

Novartis shareholders followed the Board of Directors’ recommendation, approving the proposed merger of Alcon, Inc. into Novartis…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +